Document is current
Any future updates will be listed below
-
Authors
Li, Lu
Zhang, Likun
Jiang, Wenhao
Gui, Zhiqiang
Wang, Zhihong
Zhang, Hao
He, Yi
Zhu, Yi
Guo, Tiannan
Guan, Haixia
Liu, Zhiyan
Sun, Yaoting
Gao, Jianqing
-
Funding
Funding for this research was provided by:
National Key Research and Development Program of China (2022YFF0608403)
China Postdoctoral Science Foundation (2022M722841)
- License Information
-
More Information
Article History
Accepted: 22 October 2024
First Online: 4 November 2024
Declarations
:
: The study methodologies adhered to the guidelines outlined in the Declaration of Helsinki, and the study protocol and waiver of informed consent were approved by the Ethics Committee of Westlake University [No. 20240708GTN001].
: T.G. and Y.Z. are the shareholders of Westlake Omics Inc. T.G., J.G., L.L., W.J., and Y.S. are listed as co-inventors on a patent covering the oncocytic scoring system and IDH2 as a biomarker for identifying oncocytic charatericteristics by Westlake University (CN patent application 2023 1 17340508). The remaining authors declare no competing interests.
: During the preparation of this work, the authors used ChatGPT to improve language and readability. After using this service, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.
